Most of the time, yes, but not always, and the exceptions matter. The standard logic is simple: you don’t operate on something you haven’t confirmed is cancer. A biopsy gives tissue, tissue gives a diagnosis, and that diagnosis tells you the type, grade, and molecular markers that determine whether surgery alone is enough or whether chemotherapy or radiation needs to come alongside it. That’s why biopsy remains the default before most solid tumour surgeries. But there are situations where imaging is so characteristic, the clinical picture so clear, and the risk of attempting a biopsy so significant, that an experienced team proceeds straight to surgery instead. This isn’t cutting corners, it’s a deliberate decision based on what the evidence shows for specific tumour types in specific locations.
Dr. Sandeep Nayak, Best Cancer Treatment in Bangalore, explains it this way: “A biopsy before surgery is the rule, not because it’s always strictly necessary, but because operating without knowing what you’re treating is almost always the wrong move. The exceptions exist, but they require imaging that’s unambiguous, a team that recognises what they’re looking at, and a plan that accounts for what pathology will show once the specimen is removed and examined.”
Wondering if you need a biopsy before proceeding with tumor removal?
When Surgery Can Proceed Without a Prior Biopsy?
A small number of clinical situations make pre-operative biopsy either unnecessary or genuinely harmful.
Kidney tumours with classic imaging features
A solid renal mass with the typical imaging characteristics of renal cell carcinoma on contrast CT enhancement pattern, absence of fat, solid architecture is treated surgically without pre-operative biopsy in most international guidelines. The reason is practical: biopsy of renal masses carries real complication risk, the false negative rate is non-trivial, and the surgical plan doesn’t change based on the biopsy result in most cases. The kidney comes out either way. Pathology from the surgical specimen confirms what the imaging already indicated.
Liver lesions in a patient with known cirrhosis or hepatitis
A liver mass above a certain size in a patient with underlying cirrhosis and a significantly elevated AFP is considered diagnostic of hepatocellular carcinoma without tissue confirmation in most treatment guidelines. Biopsy of a liver lesion in this context carries bleeding risk and needle tract seeding risk — and again, the clinical management doesn’t usually hinge on tissue confirmation when the imaging and clinical context are this clear.
Deep pancreatic or retroperitoneal tumours where biopsy is technically hazardous
Some tumours sit in locations where getting a needle to them safely is genuinely difficult surrounded by major vessels, inaccessible without traversing critical structures. When imaging is highly characteristic and the surgical plan would be the same regardless of biopsy result, the team may proceed directly. The surgical specimen provides the definitive pathology.
Suspected early ovarian tumours
This one is different — here the biopsy isn’t skipped because it’s unnecessary, it’s actively avoided because it’s harmful. Needling a suspected ovarian cyst risks rupturing it and spilling contents into the peritoneal cavity, which worsens staging and can seed the abdomen. Surgical removal with intraoperative frozen section is the right approach, not pre-operative biopsy. This is covered in detail in the previous blog on Can a Biopsy Cause Cancer to Spread.
When a Biopsy Is Non-Negotiable Before Surgery?
Most cancers don’t fall into the exceptions above. For these, operating without tissue confirmation is genuinely the wrong move.
When treatment before surgery changes outcomes
Breast cancer, rectal cancer, gastric cancer, certain lung cancers — these are situations where neoadjuvant chemotherapy or radiation before surgery significantly improves what the operation can achieve. You cannot give neoadjuvant treatment without knowing the cancer type, receptor status, and molecular profile. That information only comes from biopsy and pathology. Operating without it means committing to a surgical plan before knowing whether a better one exists.
When the diagnosis is genuinely uncertain
A mass that could be cancer but could also be a benign tumour, an abscess, a lymphoma, or a metastasis from an unknown primary doesn’t get operated on without tissue. The surgical approach for each of those is completely different. Cutting first and asking questions later is how patients end up with the wrong operation for the wrong diagnosis.
When molecular profiling determines the treatment plan
Targeted therapies, immunotherapy, hormone therapy — these require specific receptor or mutation status to prescribe. EGFR-positive lung cancer gets targeted oral therapy. HER2-positive breast cancer gets trastuzumab. Triple-negative breast cancer gets pembrolizumab in the right setting. None of that is possible without the biopsy that established the molecular profile. Surgery without that information leaves a treatment plan incomplete from the start.
Why Choose MACS Clinic for Cancer Diagnosis and Surgery?
Dr. Sandeep Nayak’s team at MACS Clinic decides whether pre-operative biopsy is needed based on the tumour type, location, imaging characteristics, and what the surgical plan actually requires not as a formality applied to every case regardless of context. Where biopsy is needed, it happens before any surgical date is set. Where it isn’t, the reasons are clinical and documented, not a shortcut.
Every case goes through tumour board review before surgery is planned. The pathology from the surgical specimen, intraoperative frozen section when needed, and molecular profiling post-operatively are built into the process from the start. Those who want to discuss their diagnosis can reach the team at +91 8035740000.
FAQs
Can imaging alone confirm cancer without a biopsy?
In specific situations yes — kidney tumours with classic CT features, liver masses in cirrhotic patients with high AFP, and a few others. Outside those exceptions, imaging suggests but only pathology confirms.
What happens if surgery is done without a biopsy and the mass turns out not to be cancer?
That’s exactly the risk the rule exists to prevent. Benign tumours, infections, and lymphomas all look like cancer on imaging sometimes. Operating without tissue confirmation risks an unnecessary procedure for a condition that didn’t need it.
Does the biopsy result always change the surgical plan?
Not always — which is partly why some cases proceed without one. When the surgical plan would be identical regardless of what the biopsy shows, the risk-benefit calculation shifts
How quickly can biopsy results come back?
Standard pathology is typically ready in three to five days. Molecular profiling including receptor status and mutation testing can take up to two weeks depending on the tests required.
Disclaimer: This content is published for educational and informational purposes only.